Review of NICE Technology Appraisal Guidance No.192; Gefitinib for the treatment of non-small cell lung cancer (first line), No.227; Erlotinib monotherapy for the maintenance treatment of advanced or metastatic non-small cell lung cancer, and No.258; Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Decision to defer the review

The planned date for review of the above guidance is April 2013.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full update of the appraisal.

In December 2012 we wrote to stakeholders to inform them that the consideration of a review of TA190; Pemetrexed for the maintenance treatment of non-small cell lung cancer, was to be deferred and take place within 6 months of the publication on an independent Health Technology Assessment (HTA) report on ‘First-line therapy for adult patients with non-small cell lung cancer’ that is currently being compiled by the Liverpool Review and Implementation Group (LRiG), Liverpool University.  We also notified stakeholders that TA190 for be considered for review alongside TA181; Pemetrexed for the first line treatment of non-small cell lung cancer.

There is considerable overlap between TA192, TA227, TA258 and TA181 and TA190 and it is sensible to consider the review of these two pieces of guidance together.  Consequently we have decided to defer the consideration of the review of TA192, TA227 and TA258 to take place within 6 months of the publication of the HTA paper, when they will be considered for review along with TA181 and TA190.

April 2013